

# Nicola Lehnert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6996221/publications.pdf>

Version: 2024-02-01

41  
papers

919  
citations

623188

14  
h-index

476904

29  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1766  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207. | 0.8 | 162       |
| 2  | Spectrum and functional validation of PSMB5 mutations in multiple myeloma. <i>Leukemia</i> , 2019, 33, 447-456.   | 3.3 | 93        |
| 3  | Long-Term Shedding of Influenza Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial Epidemiology in Patients with Hematological Disorders. <i>PLoS ONE</i> , 2016, 11, e0148258.   | 1.1 | 85        |
| 4  | Community acquired respiratory virus infections in cancer patients—Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. <i>European Journal of Cancer</i> , 2016, 67, 200-212.                                    | 1.3 | 66        |
| 5  | Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. <i>Nature Communications</i> , 2021, 12, 6960.  | 5.8 | 53        |
| 6  | Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. <i>Blood</i> , 2016, 127, 2155-2157.  | 0.6 | 52        |
| 7  | Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , 2020, 34, 1853-1865.   | 3.3 | 47        |
| 8  | Isavuconazole shortens the QTc interval. <i>Mycoses</i> , 2018, 61, 256-260.  | 1.8 | 45        |
| 9  | Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. <i>Cancer Medicine</i> , 2018, 7, 307-316.  | 1.3 | 42        |
| 10 | HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 367-378.   | 1.9 | 42        |
| 11 | IKZF1/3 and CRL4 <sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. <i>Haematologica</i> , 2020, 105, e237-e241.   | 1.7 | 41        |
| 12 | 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. <i>European Journal of Cancer</i> , 2021, 147, 154-160.   | 1.3 | 34        |
| 13 | Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>European Journal of Cancer</i> , 2020, 140, 86-104.  | 1.3 | 33        |
| 14 | Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. <i>Journal of Clinical Oncology</i> , 2017, 35, 3143-3152.   | 0.8 | 27        |
| 15 | Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. <i>Blood</i> , 2020, 136, 44-45.  | 0.6 | 16        |
| 16 | Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. <i>Haematologica</i> , 2022, 107, 1891-1901.  | 1.7 | 15        |
| 17 | HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, e14527-e14527.   | 0.8 | 13        |
| 18 | Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4706.  | 1.7 | 11        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Bâ€cell maturation antigenâ€specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , 2020, 147, 2029-2041.  | 2.3 | 10        |
| 20 | Cellular Immune Response after Vaccination in Patients with Cancerâ€”Review on Past and Present Experiences. <i>Vaccines</i> , 2022, 10, 182.   | 2.1 | 9         |
| 21 | Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4349-4349.  | 0.6 | 4         |
| 22 | Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-1.  | 0.6 | 4         |
| 23 | The influence of rituximab-containing chemotherapy on HCV load in patients with HCV-associated non-Hodgkinâ€™s lymphomas. <i>Annals of Hematology</i> , 2017, 96, 1501-1507.  | 0.8 | 3         |
| 24 | Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders. <i>Leukemia and Lymphoma</i> , 2018, 59, 2660-2669.  | 0.6 | 3         |
| 25 | Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma. <i>Blood</i> , 2019, 134, 1783-1783.   | 0.6 | 3         |
| 26 | Characterization of Patients with Multiple Myeloma in Long- Term Remission. <i>Blood</i> , 2018, 132, 4508-4508.  | 0.6 | 1         |
| 27 | Profiling of Oncogenic Signaling in Multiple Myeloma â€” Association with Biology, Disease Progression and Prognosis. <i>Blood</i> , 2018, 132, 3206-3206.  | 0.6 | 1         |
| 28 | The Chromosomal Abnormalities Del(17p), t(4;14), and +1q21 Predict Progression From Smoldering to Symptomatic Multiple Myeloma. <i>Blood</i> , 2012, 120, 1806-1806.  | 0.6 | 1         |
| 29 | ATG and Statins Reduce Incidence of Severe Chronic Gvhd By Distinct Mechanisms Involving CXCL9 and Kynurenine Catabolism. <i>Blood</i> , 2015, 126, 856-856.  | 0.6 | 1         |
| 30 | Parainfluenza Virus Infections in Patients with Hematologic Malignancies or Following Stem Cell Transplantation: Analysis of Clinical Characteristics, Nosocomial Transmission and Prolonged Viral Shedding. <i>Blood</i> , 2016, 128, 3401-3401.                       | 0.6 | 1         |
| 31 | BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. <i>Blood</i> , 2012, 120, 4040-4040.   | 0.6 | 1         |
| 32 | Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.. <i>Blood</i> , 2012, 120, 3086-3086.  | 0.6 | 0         |
| 33 | Continued Response off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. <i>Blood</i> , 2012, 120, 4600-4600.  | 0.6 | 0         |
| 34 | Outbreak of Nosocomial Respiratory Syncytial Virus Infections in a Hematology and Transplant Unit.. <i>Blood</i> , 2012, 120, 3032-3032.  | 0.6 | 0         |
| 35 | Analysis of Prognostic Factors in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma and Skeletal Involvement: A Novel Simple Prognostic Score Identifies a Large Group of Low Risk Patients with an Excellent Prognosis. <i>Blood</i> , 2012, 120, 1590-1590. | 0.6 | 0         |
| 36 | Analysis of Prognostic Factors and Outcome of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract. <i>Blood</i> , 2015, 126, 3964-3964.   | 0.6 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Analysis of Long-Term Survival in Multiple Myeloma Patients after First-Line Autologous Stem Cell Transplantation: Impact of Clinical Risk Factors and Duration of Response. <i>Blood</i> , 2016, 128, 4649-4649.  | 0.6 | 0         |
| 38 | Oncogene Induced Senescence As a Potential Breakpoint Mechanism Against Malignant Transformation in Plasma Cell Disorders. <i>Blood</i> , 2016, 128, 4474-4474.  | 0.6 | 0         |
| 39 | Prognostic Impact of Gastrointestinal Involvement in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 5400-5400.   | 0.6 | 0         |
| 40 | Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. <i>Blood</i> , 2021, 138, 3792-3792. | 0.6 | 0         |
| 41 | Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-14.   | 0.6 | 0         |